In another study, it was discovered that patients with lethal PCa had a significantly higher combined rate of germline BRCA/ATM alterations than those with localized PCa, and those with local disease or a diagnosis of metastases had a shorter prostate-cancer-specific survival time than non-carriers (Na et al., 2017). The gene discussed is ATM; the disease is prostate carcinoma.